Journal
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
Volume 304, Issue 1, Pages R10-R22Publisher
AMER PHYSIOLOGICAL SOC
DOI: 10.1152/ajpregu.00138.2012
Keywords
allosteric modulator; cisplatin; renal artery occlusion
Categories
Funding
- Canadian Institutes of Health Research (CIHR)
- Heart and Stroke Foundation of Canada
- Fondation de l'Hopital Sainte-Justine
- Faculte des etudes superieures et postdoctorales de l'Universite de Montreal
- CIHR Systems Biology program studentship
- CIHR Drug Design Training program studentship
- Theratechnologies
Ask authors/readers for more resources
Leduc M, Hou X, Hamel D, Sanchez M, Quiniou C, Honore J, Roy O, Madaan A, Lubell W, Varma DR, Mancini J, Duhamel F, Peri KG, Pichette V, Heveker N, Chemtob S. Restoration of renal function by a novel prostaglandin EP4 receptor-derived peptide in models of acute renal failure. Am J Physiol Regul Integr Comp Physiol 304: R10-R22, 2013. First published November 14, 2012; doi:10.1152/ajpregu.00138.2012.-Acuterenal failure (ARF) is a serious medical complication characterized by an abrupt and sustained decline in renal function. Despite significant advances in supportive care, there is currently no effective treatment to restore renal function. PGE(2) is a lipid hormone mediator abundantly produced in the kidney, where it acts locally to regulate renal function; several studies suggest that modulating EP4 receptor activity could improve renal function following kidney injury. An optimized peptidomimetic ligand of EP4 receptor, THG213.29, was tested for its efficacy to improve renal function (glomerular filtration rate, renal plasma flow, and urine output) and histological changes in a model of ARF induced by either cisplatin or renal artery occlusion in Sprague-Dawley rats. THG213.29 modulated PGE2-binding dissociation kinetics, indicative of an allosteric binding mode. Consistently, THG213.29 antagonized EP4-mediated relaxation of piglet saphenous vein rings, partially inhibited EP4-mediated cAMP production, but did not affect G alpha(i) activation or beta-arrestin recruitment. In vivo, THG213.29 significantly improved renal function and histological changes in cisplatin-and renal artery occlusion-induced ARF models. THG213.29 increased mRNA expression of heme-oxygenase 1, Bcl2, and FGF-2 in renal cortex; correspondingly, in EP4-transfected HEK293 cells, THG213.29 augmented FGF-2 and abrogated EP4-dependent overexpression of inflammatory IL-6 and of apoptotic death domain-associated protein and BCL2-associated agonist of cell death. Our results demonstrate that THG213.29 represents a novel class of diuretic agent with noncompetitive allosteric modulator effects on EP4 receptor, resulting in improved renal function and integrity following acute renal failure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available